Several groundbreaking medications are reshaping glucose treatment, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as potential candidates. Retatrutide, a twin GIP and GLP-1 site activator, exhibits significant body mass decrease coupled with improved glucose regulation. Cagrillintide, another GLP-1 activator, is presently i